NCT02208362View on ClinicalTrials.gov

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 18, 2015

Primary Completion Date

February 8, 2021

Study Completion Date

June 8, 2026

Conditions
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent WHO Grade II GliomaRecurrent WHO Grade III GliomaRefractory GlioblastomaRefractory Malignant GliomaRefractory WHO Grade II GliomaRefractory WHO Grade III Glioma
Interventions
BIOLOGICAL

Arm 1: IL13Ra2-specific CAR Tcm cells

Given via intratumoral catheter

BIOLOGICAL

Arm 2: IL13Ra2-specific CAR Tcm cells

Given via intratumoral/intracavitary catheter

BIOLOGICAL

Arm 3: IL13Ra2-specific CAR Tcm cells

Given via intraventricular catheter

BIOLOGICAL

Arm 4: IL13Ra2-specific CAR Tcm cells

Given via intratumoral or intracavitary, and via intraventricular catheter

BIOLOGICAL

Arm 5: IL13Ra2-specific CAR Tn/mem cells

Given via intratumoral or intracavitary, and via intraventricular catheter

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Magnetic Resonance Imaging

Correlative studies

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Food and Drug Administration (FDA)

FED

lead

City of Hope Medical Center

OTHER

NCT02208362 - Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma | Biotech Hunter | Biotech Hunter